Cannabidiol (CBD) + Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clinical High Risk for Psychosis (CHR)
Conditions
Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
Trial Timeline
May 1, 2026 → Dec 1, 2031
NCT ID
NCT07434973About Cannabidiol (CBD) + Placebo
Cannabidiol (CBD) + Placebo is a phase 3 stage product being developed by Jazz Pharmaceuticals for Clinical High Risk for Psychosis (CHR). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07434973. Target conditions include Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis.
What happened to similar drugs?
1 of 3 similar drugs in Clinical High Risk for Psychosis (CHR) were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07434973 | Phase 3 | Recruiting |
Competing Products
20 competing products in Clinical High Risk for Psychosis (CHR)